- CEO
- Zhi Guang Fang
- Full Time Employees
- 529
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Shanghai China
- IPO Date
- Aug 26, 2024
- Business
- Shanghai Xiao Fang Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise that specializes in the research, development, manufacturing, and commercialization of over-the-counter (OTC) external-use pharmaceuticals, topical dermatological treatments, and consumer healthcare products. Founded in 1993 as Shanghai Yunjia Huangpu Pharmaceutical Co., Ltd. and headquartered in Shanghai, China, the company operates across three core business segments: Gastrointestinal and Laxative Preparations, which includes Kaiselu (glycerin enema), glycerin enema solutions, and liquid paraffin for pediatric, adult, and geriatric constipation relief; Dermatological and Topical Formulations, marketed predominantly under its flagship Xinlong brand, comprising calamine lotion, zinc oxide ointment, Xinlong Hongtun diaper rash ointment, sulfur ointment, salicylic acid ointment, boric acid solution, urea cream, hydrocortisone butyrate cream, compound benzoic acid tincture, and povidone-iodine disinfectant solutions; and ENT and Oral Care Preparations, featuring phenol glycerin ear drops, sodium bicarbonate ear drops, Longyidian oral ulcer topical treatments, and Xiaofang Hanhan pharyngitis gargle and mouthwash solutions. Shanghai Xiao Fang Pharmaceutical Co., Ltd. serves retail consumers, community clinics, and hospital outpatient departments throughout mainland China via an extensive distribution network of retail pharmacy chains, regional pharmaceutical wholesalers, and major e-commerce healthcare platforms. In August 2024, the company achieved a major corporate milestone by completing its initial public offering (IPO) and listing its Class A shares on the Main Board of the Shanghai Stock Exchange under the ticker symbol 603207, raising approximately RMB 498.8 million in gross proceeds. Following its listing, the company has actively deployed IPO proceeds into strategic capital expansion initiatives, including the construction of a modern automated topical pharmaceutical production base in Shanghai to expand manufacturing capacity, the establishment of an advanced research and development center targeting innovative traditional Chinese medicines and specialized topical delivery systems, and the nationwide enhancement of its omnichannel retail marketing infrastructure.